Skip to main navigation Skip to search Skip to main content

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

  • Mamta Parikh
  • , Catherine Tangen
  • , Maha H.A. Hussain
  • , Shilpa Gupta
  • , Sam Callis
  • , Yeonjung Jo
  • , Andrea Harzstark
  • , Channing J. Paller
  • , Saby George
  • , Matthew R. Zibelman
  • , Heather H. Cheng
  • , Benjamin L. Maughan
  • , Jingsong Zhang
  • , Russell K. Pachynski
  • , Alan H. Bryce
  • , Daniel W. Lin
  • , David I. Quinn
  • , Seth P. Lerner
  • , Ian M. Thompson
  • , Tanya B. Dorff
    • Primo N. Lara, Neeraj Agarwal
  • University of California at Davis
  • SWOG Statistics and Data Management Center
  • Northwestern University
  • Cleveland Clinic Foundation
  • University of Utah
  • Kaiser Permanente
  • Johns Hopkins University
  • Roswell Park Cancer Institute
  • Fred Hutchinson Cancer Research Center
  • Moffitt Cancer Center
  • Washington University St. Louis
  • University of Southern California
  • Baylor College of Medicine
  • University of Texas Health Science Center at San Antonio
  • City of Hope National Medical Center

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry